Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2009-10-02

Clinical Trial Update: Long Term Safety of SL77.0499-10 (Alfuzosin) in Patients With BPH [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update reporting long-term safety data for Alfuzosin (SL77.0499-10) in men with Benign Prostatic Hyperplasia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Alfuzosin (alfuzosin)

Snippet

Sponsor: Sanofi | Conditions: Benign Prostatic Hyperplasia | Phase 3 | Status: COMPLETED